Advanced search
Publication Cover
Future Medicinal Chemistry Volume 1, 2009 - Issue 5
Submit an article Journal homepage
219
Views
0
CrossRef citations to date
0
Altmetric
Review

Fluorinase: A Tool for the Synthesis of 18F-Labeled Sugars and Nucleosides for Pet

Mayca OnegaUniversity of St Andrews, School of Chemistry and Centre for Biomolecular Sciences, North Haugh, St Andrews, KY16 9ST, Fife, UKView further author information
,
Margit WinklerUniversity of St Andrews, School of Chemistry and Centre for Biomolecular Sciences, North Haugh, St Andrews, KY16 9ST, Fife, UKView further author information
&
David O‘HaganUniversity of St Andrews, School of Chemistry and Centre for Biomolecular Sciences, North Haugh, St Andrews, KY16 9ST, Fife, UKCorrespondence[email protected]
View further author information
Pages 865-873 | Published online: 19 Aug 2009

Bibliography

  • O´Hagan D , SchaffrathC, CobbSL, HamiltonJTG, MurphyCD. Enzyme catalysed organofluorine synthesis.Nature416, 279 (2002).
  • Schaffrath C , DengH, O´HaganD. Isolation and characterisation of 5´-fluorodeoxyadenosine synthetase, a fluorination enzyme from Streptomyces cattleya. FEBS Lett.547, 111–114 (2003).
  • Dong C , HuangF, DengHet al. Crystal structure and mechanism of a bacterial fluorinating enzyme. Nature 427, 561–465 (2004).
  • Phelps ME , HoffmanEJ, MullaniNA, Ter-PogissianMM. Application of annihilhation and coincidence detection to transaxial reconstruction tomography.J. Nucl. Med.16, 210–224 (1975).
  • Muehllehner G , KarpJS. Positron emission tomography.Phy. Med. Biol.51, 117–137 (2006).
  • Dollé F , RoedaD, KuhnastB, Lasne M-C. Fluorine-18 chemistry for molecular imaging with PET. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands 4–65 (2008).
  • Fowler JS . The synthesis and application of F-18 compounds in positron emission tomography. In: Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications. Filler R, Kobayashi Y, Yagupolskii LM (Eds). Elsevier, Amsterdam, The Netherlands, 309–338 (1993).
  • Schiepers C . Positron emission tomography: a coming of age?Eur. J. Intern. Med.15, 143–146 (2004).
  • Chen W . Clinical applications of PET in brain tumors.J. Nucl. Med.48, 1468–1481 (2007).
  • Wong DF , BrašicJR. In vivo imaging of neurotransmitter systems in neuropsychiatry. Clinical Neurosci. Res.1, 35–45 (2001).
  • Kopka K , WagnerS, SchäfersM, FaustA, SchoberO, HaufeG. 18F-Labeled PET-tracers for cardiological imaging. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands 85–139 (2008).
  • Någren K , RinneJO. Application of 18F-PET imaging for the study of Alzheimer’s disease. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands, 67–84 (2008).
  • Pike KE , SavageG, VillemagneVLet al. β-amyloid imaging and memory in non-demented individuals. Evidence for preclinical Alzheimer’s disease. Brain 130, 2837–2844 (2007).
  • Rowe CC , NgS, AckermannUet al. Imaging β-amyloid burden in aging and dementia. Neurology 15, 1718–1725 (2007).
  • Foster NL , HeidebrinkJL, ClarkCMet al. FDG-PET improves accuracy in distinguishing frontotemporal dementia Alzheimer’s disease. Brain 130, 2616–2635 (2007).
  • Didelot A , RyvlinP, LotheA, MerletI, HammersA, MauguièreF. PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy. Brain131, 1–14 (2008).
  • Milak MS , ParseyRV, KeilpJ, OquendoMA, MaloneKM, MannJJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder.Arch. Gen. Psychiatry62, 397–408 (2005).
  • Kennedy S H, Evans KR, Krüger S et al. Changes in regional brain glucose metabolism measured by positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry158, 899–905 (2001).
  • Mamo D , KapurS, KeshavanMet al. D-2 receptor occupancy olanzapine pamoate depot using positron emission tomography: an open-label study on patients with schizophrenia. Neuropsychopharmacology 33, 298–304 (2008).
  • Okubo Y , SuharaT, SuzukiKet al. Decreases prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634–636 (1997).
  • Gerasimov MR , DeweySL. Development of a GABAergic treatment for substance abuse using PET.Drug Develop. Res.59, 240–248 (2003).
  • Lingford-Hughes AR , DaviesSJC, McIverS, WilliamsTM, DaglishMRC, NuttDJ. Addiction.Brit. Med. Bull.65, 209 (2003).
  • Neves AA , BrindleKM. Assessing responses to cancer therapy using molecular imaging.Biochim. Biophys. Acta1766, 242–261 (2006).
  • Weber WA . Use of PET for monitoring cancer therapy and predicting outcome.J. Nucl. Med.46, 983–995 (2005).
  • Strauss LG , ContiPS. The applications of PET in clinical oncology.J. Nucl. Med.32, 623–648 (1991).
  • Hermann K , KrauseBJ. [18F]-Labeled PET and PET/CT compounds in oncology. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands, 141–196 (2008).
  • West CML , JonesT, PriceP. The potential of positron emission tomography to study anti-cancer drug resistance.Nature Rev. Cancer4, 457–469 (2004).
  • Gupta N , PricePM, AboagyeEO. PET for in vivo pharmacokinetic and pharmocodynamic measurements. Eur. J. Cancer38, 2094–2107 (2002).
  • Gee AD . Neuropharmacology and drug development.Br. Med. Bull.65, 169 (2003).
  • Ido T , WanWN, CasellaVet al. Labelled 2-deoxy-D-glucose analogues. 18F-labelled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and [14C] 2-deoxy-2-fluoro-D-glucose. J. Label. Cmpd Radiopharm. 14, 175–183 (1978).
  • Lasne M -C, Perrio C, Rouden J et al. Chemistry of b+-emitting compounds based of fluorine-18. In: Topics in Current Chemistry (Volume 2). Springer-Verlag, Berlin, Heildelberg, Germany, 201–258 (2002).
  • Cai L , LuS, PikeVW. Chemistry with [18F]fluoride ion. Eur. J. Org. Chem.2853–2873 (2008).
  • Isanbor C , O‘HaganD. Fluorine in medicinal chemistry: Anticancer agents.J. Fluorine Chem.127, 303–319 (2006).
  • Le Bars D . Fluorine-18 and medical imaging. Radiopharmaceuticals for positron emission tomographyJ. Fluorine Chem.127, 1488–1493 (2006).
  • Gambhir SS , CzerninJ, SchwimmerJet al. A tabulated survey of the FDG PET literature. J. Nucl. Med. 42, S1–S93 (2001).
  • Phelps ME , MazziottaJC. Positron emission tomography: human brain function and biochemistry.Science228, 799–809 (1985).
  • Delgado-Bolton RC , Fernández-PérezC, González-MatéA, CarrerasJL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors.J. Nucl. Med.44, 1301–1314 (2003).
  • Som P , AtkinsHL, BandoypadhyayDet al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J. Nucl. Med. 21, 670–675 (1980).
  • Smith TAD . Mammalian hexokinases and their abnormal expression in cancer.Br. J. Biomed. Sci.57, 170–178 (2000).
  • Schelbert HR , HohCK, RoyalHDet al. Procedure guideline for tumor imaging using fluorine-18-FDG . J. Nucl. Med. 39, 1302–1305 (1998).
  • Varagnolo L , StokkelMPM, MazziU, PauwelsEKJ. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl. Med. Biol.27, 103–112 (2000).
  • Beuthien-Baumann B , HamacherK, OberdorferF, SteinbachJ. Preparation of fluorine-18 labelled sugars and derivatives and their application as tracer for positron-emission-tomography.J. Carbohydr. Res.327, 107–118 (2000).
  • Ishiwata K , KimuraY, de Vries EFJ, Elsinga P. PET Tracers for mapping adenosine receptors as probes for diagnosis for CNS disorders. Cent. Nerv. Syst. Agents. Med. Chem.7, 57–77 (2007).
  • Damaraju VL , DamarajuS, YoungJDet al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22, 7524–7536 (2003).
  • Pennycooke M , ChaudaryN, ShuralyovaI, ZhangY, CoeIR. Differential expression of human nucleoside transporters in normal and tumor tissue.Biochem. Biophys. Res. Commun.280, 951–959 (2001).
  • Baldwin SA , MackeyJR, CassCE, YoungJD. Nucleoside transporters: molecular biology and implications for therapeutic development.Mol. Med. Today5, 216–224 (1999).
  • Thorn JA , JarvisSM. Adenosine transporters.Gen. Pharmac.27, 613–620 (1996).
  • Spicuzza L , Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur. J. Pharmacol.533, 77–88 (2006).
  • Klotz K -N, Falgner N, Kachler S et al. [3H] EMADO– a novel tritiated agonist selective for the human adenosine A3 receptor. Eur. J. Pharmacol.556, 14–18 (2007).
  • Cho SY , PolsterJ, EnglesJM, HiltonJ, AbrahamEH, WahlRL. In vitro evaluation of adenosine 5´-monophosphate as an imaging agent of tumor metabolism. J. Nucl. Med.47, 837–845 (2006).
  • Mathews WB , NakamotoY, AbrahamEHet al. Synthesis and biodistribution of [11C]adenosine 5´-monophosphate ([11C]AMP). Mol. Imaging Biol. 7, 203–208 (2005).
  • Alauddin MM , ShahinianA, ParkR, TohmeM, FissekisJD, ContiPS. Biodistribution and PET imaging of [18F]-fluoroadenosine derivatives. Nucl. Med. Biol.34, 267–272 (2007).
  • Alauddin MM , FissekisJD, ContiPS. Synthesis of [18F]-labeled adenosine analogues as potential PET imaging agents. J. Labelled Cmpd. Radiopharm.46, 805–814 (2003).
  • Nanni C , Di LeoK, TonelliRet al. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur. J. Nucl. Med. Mol. I.34, 755–762 (2007).
  • Kenny LM , AboagyeEO, PricePM. Positron emission tomography imaging of cell proliferation in oncology.Clin. Oncol.16, 176–185 (2004).
  • Lehel S z, Horváth G, Boros I, Mikecz P, Márián T, Trón L. Synthesis of 5´-deoxy-5´-[18F]fluoro-adenosine by radiofluorination of 5´-deoxy-5´-haloadenosine derivates. J. Radioanal. Nucl. Chem.245, 399–401 (2000).
  • Lehel SZ , HorváthG, BorosI, MáriánT, TrónL. The nucleophilic substitution reaction for [18F]fluoride-ion on the series of N6-benzoyl-2´,3´-isopropylideneadenosine-5´-sulfonates. J. Radioanal. Nucl. Chem.251, 413–416 (2002).
  • Antoni G , OmuraH, IkemotoM, MoulderR, WatanabeY, LångströmB. Enzyme catalysed synthesis of l-[4–11C]aspartate and l-[5–11C]glutamate. J. Labelled Cmpd. Radiopharm.44, 287–294 (2001).
  • Lui E , ChirakalR, FirnauG. Enzymatic synthesis of (-)-6-[18F]-fluoronorepinephrine from 6-[18F]-fluorodopamine by dopamine β-hydroxylase. J. Labelled Cmpd Radiopharm.41, 503–521 (1998).
  • Bjurling P , AntoniG, WatanabeY, LångströmB. Enzymatic synthesis of carboxy-11C-labelled l-tyrosine, l-DOPA, l-tryptophan and 5-hydroxy-L-tryptophan. Acta Chem. Scand.4, 178–182 (1990).
  • Cadicamo CD , CourtieuJ, DengH, MeddourA, O‘HaganD. Enzymatic fluorination in Streptomyces cattleya takes place with an inversion of configuration consistent with an SN2 reaction mechanism. ChemBioChem5, 685–690 (2004).
  • Martarello L , SchaffrathC, DengH, GeeAD, LockhartA, O‘HaganD. The first enzymatic method for C-F-18 bond formation: the synthesis of 5´-[F-18]-fluoro-5´-deoxyadenosine for imaging with PET.J. Label. Cmpd Radiopharm.46, 1181–1189 (2003).
  • Deng H , CobbSL, McEwanARet al. The fluorinase from Streptomyces cattleya is also a chlorinase. Angew. Chemie Int. Ed. 45, 759–762 (2006).
  • Deng H , CobbSL, GeeADet al. Fluorinase mediated C-18F bond formation, an enzymatic tool for PET labelling. Chem. Commun. 652–654 (2006).
  • Cobb SL , DengH, McEwanAR, NaismithJH, O‘HaganD, RobinsonDA. Substrate specificity in enzymatic fluorination. The fluorinase from Streptomyces cattleya accepts 2´-deoxyadenosine substrates. Org. Biomol. Chem.4, 1458–1460 (2006).
  • Winkler M , DomarkasJ, SchweigerLF, O‘HaganD. Fluorinase-coupled base swaps: synthesis of [18F]-5´-deoxy-5´-fluorouridines. Angew. Chem. Int. Ed.47, 10141–10143 (2008).
  • O‘Hagan D , DengH, SchaffrathC. Fluorometabolite biosynthesis and the fluorinase from Streptomyces cattleya. Nat. Prod. Rep.21, 773–784 (2004).
  • Onega M , McGlincheyRP, DengH, HamiltonJTG, O‘HaganD. The identification of (3R,4S)-5-fluoro-5-deoxy-D-ribulose-1-phosphate as an intermediate in fluorometabolite biosynthesis in Streptomyces cattleya. Bioorg. Chem.35, 375–385 (2007).
  • Deng H , CrossSM, McGlincheyRP, HamiltonJTG, O‘HaganD. In vitro reconstituted biotransformation of 4-fluorothreonine from fluoride ion: application of the fluorinase. Chem. Biol.15, 1268–1276 (2008).
  • Drager G , KissC, KunzU, KirschningA. Enzyme-purification and catalytic transformations in a microstructured PASSflow reactor using a new tyrosine-based Ni-NTA linker system attached to a polyvinylpyrrolidinone-based matrix. Org. Biomol. Chem.5, 3657–3664 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.